List of Victoza drug patents
Victoza is owned by Novo Nordisk Inc.
Victoza contains Liraglutide Recombinant.
Victoza has a total of 14 drug patents out of which 3 drug patents have expired.
Expired drug patents of Victoza are:
- US8846618
- US8846618*PED
- US6268343
Victoza was authorised for market use on 25 January, 2010.
Victoza is available in solution;subcutaneous dosage forms.
Victoza can be used as method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide, a method for improving glycemic control in adults with type 2 diabetes mellitus.
The generics of Victoza are possible to be released after 09 July, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2022
(5 months ago) | |
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846618 | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Jun, 2022
(7 months ago) | |
|
US8846618
(Pediatric) | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Dec, 2022
(a month ago) | |
|
US6268343
(Pediatric) | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Feb, 2023
(24 days from now) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(4 months from now) | |
|
US8579869
(Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(10 months from now) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 3 months from now) | |
|
US7762994
(Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 9 months from now) | |
|
US8114833
(Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(3 years from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(9 years from now) | |
|
US9265893
(Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(10 years from now) | |
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
|
US9968659
(Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 17, 2022 |
| Pediatric Exclusivity (PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide; A method for improving glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US6268343 | NA | Derivatives of GLP-1 analogs |
Aug, 2022
(5 months ago) |
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic